1-16 of 16
Britta Besemer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Clinical Trials & Observations
Cyrille Touzeau, Amrita Y Krishnan, Philippe Moreau, Aurore Perrot, Saad Z Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay K. Nooka, Thomas G Martin, Lionel Karlin, Xavier Leleu, Nizar J. Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca Verona, Suzette Girgis, Xin Miao, Clarissa Uhlar, Katherine Chastain, Alfred Garfall
Journal: Blood
Blood blood.2023023616.
https://doi.org/10.1182/blood.2023023616
Published: 2024
Includes: Supplemental data
Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Noffar Bar, Maria Victoria Mateos, Paz Ribas, Markus Hansson, Laura Paris, Craig C. Hofmeister, Paula Rodriguez Otero, Maria Aranzazu Bermúdez, Thomas Martin, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas Rodriguez, Claudio Cerchione, Javier De La Rubia, Albert Oriol, Heidi Waibel, Britta Besemer, Ethan Thompson, Brian Kiesel, Jinjie Chen, Alexander Chung, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano Costa
Journal: Blood
Blood (2023) 142 (Supplement 1): 2011.
https://doi.org/10.1182/blood-2023-180013
Published: 2023
Journal Articles

Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany

Christine Riedhammer, Florian Bassermann, Britta Besemer, Moritz Bewarder, Franziska Brunner, Alexander Carpinteiro, Hermann Einsele, Josefine Faltin, Jan Frenking, Deniz Gezer, Sarah Goldman-Mazur, Mathias Hanel, Marion Hoegner, K. Martin Kortüm, Jan Krönke, Miriam Kull, Theo Leitner, Christoph Mann, Rabea Mecklenbrauck, Maximilian Merz, Anke Morgner, Axel Nogai, Marc S. Raab, Raphael Teipel, Ralph Wäsch, Leo Rasche
Journal: Blood
Blood (2023) 142 (Supplement 1): 3329.
https://doi.org/10.1182/blood-2023-180032
Published: 2023
Journal Articles

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Gigi Nu Hoang Quy Ton, Katharina Kriegsmann, Mohamed H.S. Awwad, Axel Benner, Uta Bertsch, Britta Besemer, Mathias Hänel, Roland Fenk, Jana Schlenzka, Markus Munder, Jan Dürig, Igor Wolfgang Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Andreas Neubauer, Niels Weinhold, Christof Scheid, Roland Schroers, Ivana von Metzler, Aneta Schieferdecker, Jörg Thomalla, Peter Reimer, Rolf Mahlberg, Ullrich Graeven, Stephan Kremers, Uwe Martens, Christian Kunz, Manfred Hensel, Andrea Seidel-Glätzer, Katja Weisel, Hans Salwender, Carsten Müller-Tidow, Marc S. Raab, Hartmut Goldschmidt, Elias K. Mai, Michael Hundemer
Journal: Blood
Blood (2023) 142 (Supplement 1): 1991.
https://doi.org/10.1182/blood-2023-189169
Published: 2023
Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, Marc S. Raab, Sandra Sauer, Maximilian Merz, Elias K. Mai, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Peter Brossart, Martin Goerner, Stefan Klein, Bertram Glass, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Hänel, Ivana von Metzler, Lindemann Hans W., Christof Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel, Hartmut Goldschmidt
Journal: Blood
Blood (2023) 142 (Supplement 1): 782.
https://doi.org/10.1182/blood-2023-178835
Published: 2023
Journal Articles

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Esther Gonzalez Garcia, Britta Besemer, Marta Sonia Gonzalez Perez, Mohamad Mohty, Joanne Lindsey-Hill, Suriya Kirkpatrick, Michel Delforge, Emanuele Angelucci, Francesco Di Raimondo, Ravi Vij, Margaret Doyle, Kathleen Gray, Claire Albrecht, Vadim Strulev, Imène Haddad, Silva Saarinen, Lada Mitchell, Jozefien Buyze, Katja Weisel
Journal: Blood
Blood (2023) 142 (Supplement 1): 4698.
https://doi.org/10.1182/blood-2023-181235
Published: 2023
Journal Articles

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Clinical Trials & Observations Brief Report
Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M. Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, K. Martin Kortüm, Carsten Müller-Tidow, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Niels Weinhold, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab
Journal: Blood
Blood (2023) 141 (14): 1685–1690.
https://doi.org/10.1182/blood.2022017789
Published: 2023
Includes: Supplemental data
Journal Articles

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Katja Weisel, Britta Besemer, Mathias Haenel, Raphael Lutz, Christoph Mann, Markus Munder, Martin Goerner, Hans Christian Reinhardt, Axel Nogai, Yon-Dschun Ko, Maike De Wit, Hans Salwender, Christoph Scheid, Ullrich Graeven, Rudolf Peceny, Peter Staib, Annette Dieing, Anna Jauch, Manola Zago, Axel Benner, Diana Tichy, Carsten Bokemeyer, Hartmut Goldschmidt, Lisa B. Leypoldt
Journal: Blood
Blood (2022) 140 (Supplement 1): 1836–1838.
https://doi.org/10.1182/blood-2022-156309
Published: 2022
Journal Articles

Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome

Simon Steiger, Raphael Lutz, Nina Prokoph, Subarna Palit, Stephan M Tirier, Philipp Reichert, Anja Baumann, Nadine Hefner, Sabrina Schumacher, Dominik Vonficht, Florian Grünschläger, Alexandra M Poos, Lukas John, Laleh Haghverdi, Jan-Philipp Mallm, Elias K Mai, Mirco Friedrich, Katharina Kriegsmann, Mohamed H.S. Awwad, Anna Jauch, Uta Bertsch, Diana Tichy, Carsten Müller-Tidow, Roland Schroers, Hans Salwender, Britta Besemer, Roland Fenk, Katja Weisel, Hartmut Goldschmidt, Stefanie Huhn, Michael Hundemer, Karsten Rippe, Simon Haas, Niels Weinhold, Marc S Raab
Journal: Blood
Blood (2022) 140 (Supplement 1): 2083–2085.
https://doi.org/10.1182/blood-2022-168685
Published: 2022
Journal Articles

Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network

Elias K Mai, Thomas Hielscher, Uta Bertsch, Hans Salwender, Sonja Zweegman, Markus Munder, Lucia Pantani, Peter Brossart, Meral Beksac, Igor Wolfgang Blau, Marc-Steffen Raab, Jan Dürig, Nicola Giesen, Britta Besemer, Roland Fenk, Peter Reimer, Bronno van der Holt, Mathias Haenel, Ivana v. Metzler, Ullrich Graeven, Mario Boccadoro, Christof Scheid, Meletios A. Dimopoulos, Katja Weisel, Michele Cavo, Pieter Sonneveld, Hartmut Goldschmidt
Journal: Blood
Blood (2021) 138 (Supplement 1): 3792.
https://doi.org/10.1182/blood-2021-145289
Published: 2021
Journal Articles

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Philippe Moreau, Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesus San-Miguel, Albert Oriol, Ajay K. Nooka, Thomas Martin, Laura Rosinol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, Maria-Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez-López, Surbhi Sidana, Lixia Pei, Danielle Trancucci, Raluca I. Verona, Suzette Girgis, Yunsi Olyslager, Mindy Jaffe, Clarissa M. Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Y. Krishnan
Journal: Blood
Blood (2021) 138 (Supplement 1): 896.
https://doi.org/10.1182/blood-2021-147915
Published: 2021
Journal Articles

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Britta Besemer, Mathias Haenel, Kaya Miah, Roland Fenk, Jana Schlenzka, Markus Munder, Jan Dürig, Igor Wolfgang Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Christina Kunz, Andreas Neubauer, Christof Scheid, Roland Schroers, Ivana v. Metzler, Aneta Schieferdecker, Joerg Thomalla, Peter Reimer, Rolf Mahlberg, Ullrich Graeven, Stephan Kremers, Uwe M. Martens, Christian Kunz, Manfred Hensel, Andrea Seidel-Glaetzer, Katja Weisel, Marc-Steffen Raab, Hans Salwender
Journal: Blood
Blood (2021) 138 (Supplement 1): 486.
https://doi.org/10.1182/blood-2021-147323
Published: 2021
Journal Articles

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Hartmut Goldschmidt, Elias K Mai, Eva Nievergall, Roland Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana v. Metzler, Mathias Haenel, Christoph Mann, Anne-Marie Asemissen, Bernhard Heilmeier, Stefanie Huhn, Katharina Kriegsmann, Niels Weinhold, Steffen P. Luntz, Tobias A. W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Cyrus Khandanpour, Wolfgang Knauf, Markus Munder, Thomas Geer, Hendrik Riesenberg, Joerg Thomalla, Martin Hoffmann, Marc-Steffen Raab, Hans Salwender, Katja Weisel
Journal: Blood
Blood (2021) 138 (Supplement 1): 463.
https://doi.org/10.1182/blood-2021-145097
Published: 2021
Journal Articles

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

Marc S. Raab, MD, Nicola Giesen, MD, Christof Scheid, MD, Britta Besemer, Kaya Miah, Axel Benner, Ivana Metzler, MD, Cyrus Khandanpour, PD, MD, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, MD, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Hartmut Goldschmidt, MD, Katja Weisel, MD, Manik Chatterjee
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-142600
Published: 2020
Journal Articles

Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial

Katja C. Weisel, Hans Jürgen Salwender, Christof Scheid, MD, Manola Zago, Britta Besemer, Mathias Hänel, MD, Jan Dürig, MD, Markus Munder, MD, Hans-Walter Lindemann, Anja Seckinger, Christina Kunz, Axel Benner, Dirk Hose, MD, Anna Jauch, Lothar Kanz, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1849.
https://doi.org/10.1182/blood.V130.Suppl_1.1849.1849
Published: 2017
Journal Articles

High-Cut Off Dialysis In Multiple Myeloma Patients With Dialysis Dependent Acute Renal Failure Shows Durable Renal Recovery: A Long-Term Follow Up Analysis

Britta Besemer, M.D., Martina Guthoff, Lothar Kanz, MD, Nils Heyne, Katja Weisel, MD
Journal: Blood
Blood (2013) 122 (21): 3199.
https://doi.org/10.1182/blood.V122.21.3199.3199
Published: 2013